Porcine skin gelatin hydrolysate as a dipeptidyl peptidase IV inhibitor improves glycemic control in streptozotocin-induced diabetic rats

Journal of Functional Foods

Volumn 11, Issue C, 2014, Pages 235-242

  Huang, Shih Li ^a   Hung, Chuan Chuan ^b,c   Jao, Chia Ling ^d   Tung, Yu Shan ^b   Hsu, Kuo Chiang ^b,c  

^a NATIONAL KAOHSIUNG UNIVERSITY OF HOSPITALITY AND TOURISM   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c ASIA UNIVERSITY   (Taiwan)

^d TUNG FANG DESIGN UNIVERSITY   (Taiwan)

Author keywords

Dipeptidyl peptidase IV inhibitor; GLP 1; Insulin; Porcine skin gelatin; Type 2 diabetes

Indexed keywords

ANIMALIA; RATTUS; SUS;

EID: 84926315093     PISSN: 17564646     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jff.2014.09.010     Document Type: Article

References (33)

1. Aart, V. A., Catharina, M. J., Zeeland-Wolbers, V., Maria, L. A., Gilst, V., Hendrikus, W., Nelissen, B. J. H., & Maria, J. W. P. (2009) WO 2009/128713 2009, Egg protein hydrolysates.
2. Ahrén B. DPP-IV inhibitors. Best Practice & Research Clinical Endocrinology & Metabolism 2007, 21:517-533.
3. Balas B., Baig M.R., Watson C., Dunning B.E., Ligueros-Saylan M., Wang Y., He Y.L., Darland C., Holst D.J., Deacon C.F., Cusi K., Mari A., Foley J.E., DeFronzo R.A. The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients. The Journal of Clinical Endocrinology & Metabolism 2007, 92:1249-1255.
4. Cohen M., Fruitier-Amaudin I., Piot J.M. Hemorphins: Substrate and/or inhibitors of dipeptidyl peptidase IV. Hemorphins N-terminus sequence influence on the interaction between hemorphins and DPPIV. Biochimie 2004, 86:31-37.
5. Creutzfeldt W. The entero-insular axis in type 2 diabetes-incretins as therapeutic agents. Experimental and Clinical Endocrinology & Diabetes 2001, 109:S288-S300.
6. Cunningham D.F., O'Connor B. Proline specific peptidases. Biochimica et Biophysica Acta 1997, 1343:160-186.
7. Davy A., Thomsen K.K., Juliano M.A., Alves L.C., Svendsen I., Simpson D.J. Purification and characterization of barley dipeptidyl peptidase IV. Plant Physiology 2000, 122:425-432.
8. Deacon C.F., Holst J.J. Dipeptidyl peptidase IV inhibitors: A promising new therapeutic approach for the management of type 2 diabetes. The International Journal of Biochemistry & Cell Biology 2006, 38:831-844.
9. Deacon C.F., Nauck M.A., Meier J., Hücking K., Holst J.J. Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. The Journal of Clinical Endocrinology & Metabolism 2000, 85:3575-3581.
10. Ferraro V., Cruz I.B., Jorge R.F., Malcata F.X., Pintado M.E., Castro P.M.L. Valorisation of natural extracts from marine source focused on marine by-products: A review. Food Research International 2010, 43:2221-2233.
11. Gooben K., Gräber S. Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: Systematic review and meta-analysis. Diabetes, Obesity and Metabolism 2012, 14:1061-1072.
12. Hira T., Mochida T., Miyashita K., Hara H. GLP-1 secretion is enhanced directly in the ileum but indirectly in the duodenum by a newly identified potent stimulator, zein hydrolysate, in rats. American Journal of Physiology. Gastrointestinal and Liver Physiology 2009, 297:G663-G671.
13. Huang S.L., Jao C.L., Ho K.P., Hsu K.C. Dipeptidyl-peptidase IV inhibitory activity of peptides derived from tuna cooking juice hydrolysates. Peptides 2012, 35:114-121.
14. Kieffer T.J., McIntosh C.H.S., Pederson R.A. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 1995, 136:3585-3597.
15. Kim S.J., Nian C., Doudet D.J., McIntosh C.H.S. Inhibition of dipeptidyl peptidase IV with sitagliptin (MK0431) prolongs islet graft survival in streptozotocin-induced diabetic mice. Diabetes 2008, 57:1331-1339.
16. Kojima K., Ham T., Kato T. Rapid chromatographic purification of dipeptidyl peptidase IV in human submaxillary gland. Journal of Chromatography 1980, 189:233-240.
17. Lacroix I.M.E., Li-Chan E.C.Y. Evaluation of the potential of dietary proteins as precursors of dipeptidyl peptidase (DPP)-IV inhibitors by an in silico approach. Journal of Functional Foods 2012, 4:403-422.
18. Li-Chan E.C.Y., Huang S.L., Jao C.L., Ho K.P., Hsu K.C. Peptides derived from Atlantic salmon skin gelatin as dipeptidyl-peptidase IV inhibitors. Journal of Agricultural and Food Chemistry 2012, 60:973-978.
19. Mari A., Sallas W.M., He Y.L., Watson C., Ligueros-Saylan M., Dunning B.E., Deacon C.F., Holst J.J., Foley J.E. Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed β-cell function in patients with type 2 diabetes. The Journal of Clinical Endocrinology & Metabolism 2005, 90:4888-4894.
20. Matsuyama-Yokono A., Tahara A., Nakano R., Someya Y., Shiraki K., Hayakawa M., Shibasaki M. Antidiabetic effects of dipeptidyl peptidase-IV inhibitor and sulfonylureas in streptozotocin-nicotinamide-induced mildly diabetic mice. Metabolism: Clinical and Experimental 2009, 58:379-386.
21. Mitani H., Takimoto M., Hughes T.E., Kimura M. Dipeptidyl peptidase IV inhibition improves impaired glucose tolerance in high-fat diet-fed rats: Study using a Fischer 344 rat substrain deficient in its enzyme activity. The Japanese Journal of Pharmacology 2002, 88:442-450.
22. Murugan P., Pari L. Antioxidant effect of tetrahydrocurcumin in streptozotocin-nicotinamide induced diabetic rats. Life Sciences 2006, 79:1720-1728.
23. Olansky L. Do incretin-based therapies cause acute pancreatitis?. Journal of Diabetes Science and Technology 2010, 4:228-229.
24. Pieter, B. J.-W. (2006) WO 2006/068480 2006, Protein hydrolysate enriched in peptides inhibiting DPP-IV and their use.
25. Pospisilik J.A., Martin J., Doty T., Ehses J.A., Pamir N., Lynn F.C., Piteau S., Demuth H.U., McIntosh C.H., Pederson R.A. Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats. Diabetes 2003, 52:741-750.
26. Pospisilik J.A., Stafford S.G., Demuth H.U., McIntosh C.H.S., Pederson R.A. Long-term treatment with dipeptidyl peptidase IV inhibitor improves hepatic and peripheral insulin sensitivity in the VDF Zucker rat. Diabetes 2002, 51:2677-2683.
27. Poucher S.M., Cheetham S., Francis J., Zinker B., Kirby M., Vickers S.P. Effects of saxagliptin and sitagliptin on glycemic control and pancreatic ß-cell mass in a streptozotocin-induced mouse model of type 2 diabetes. Diabetes, Obesity & Metabolism 2012, 14:918-926.
28. Reimer R.A. Meat hydrolysate and essential amino acid-induced glucagon-like peptide-1 secretion, in the human NCI-H716 enteroendocrine cell line, is regulated by extracellular signal-regulated kinase1/2 and p38 mitogen-activated protein kinases. Journal of Endocrinology 2006, 191:159-170.
29. Scheen A. Gliptins (dipeptidyl peptidase-4 inhibitors) and risk of acute pancreatitis. Expert Opinion on Drug Safety 2013, 12:545-557.
30. Tabata Y., Ikada Y. Protein release from gelatin matrices. Advanced Drug Delivery Reviews 1998, 31:287-301.
31. Tulipano G., Sibilia V., Caroli A.M., Cocchi D. Whey proteins as source of dipeptidyl dipeptidase IV (dipeptidyl peptidase-4) inhibitors. Peptides 2011, 32:835-838.
32. Uchida M., Ohshiba Y., Orie M. Novel dipeptidyl peptidase-4-inhibiting peptide derived from β-lactoglobulin. Journal of Pharmacological Science 2011, 117:63-66.
33. Umezawa H., Aoyagi T., Ogawa K., Naganawa H., Hamada M., Takeuchi T. Diprotins A and B, inhibitors of dipeptidyl aminopeptidase IV, produced by bacteria. The Journal of Antibiotics 1984, 37:422-425.